New Presentation of Aggrastat FDA-Approved

The new presentation was in response to feedback from interventional cardiologists and catheterization nurses
The new presentation was in response to feedback from interventional cardiologists and catheterization nurses

Medicure announced that the Food and Drug Administration (FDA) has approved a new product presentation for Aggrastat (tirofiban HCl). 

The new 15mL bolus vial is a concentrated, premixed vial intended specifically for delivery of Aggrastat bolus doses (25mcg/kg). This new presentation was created in response to feedback from interventional cardiologists and catheterization lab nurses. Although the current intravenous (IV) bag format can be used to deliver the high dose bolus and the maintenance infusion, some healthcare professionals and hospital catheterization labs have expressed a preference to administer the initial bolus dose with a small drug volume. 

Related Articles

Aggrastat, an antiplatelet (GP IIb/IIIa blocker), is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Aggrastat is already available as a 50mcg/mL premixed solution in 100mL and 250mL IV bags.

The bolus vials will launch at the start of the 4th quarter of 2016. 

For more information call (800) 509-0544 or visit Aggrastat.com.

Loading links....